COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
11/03/2026
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial [...]
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
11/03/2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, [...]
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
11/03/2026
WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company’s progress in [...]
Nyxoah Participera à la 36ème Conférence Annuelle Oppenheimer Healthcare MedTech & Services
11/03/2026
Nyxoah Participera à la 36ème Conférence Annuelle Oppenheimer Healthcare MedTech & Services Mont-Saint-Guibert, Belgique – 11 mars 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » [...]
LogicMark, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
11/03/2026
LOUISVILLE, Ky., March 11, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK), a provider of emergency response systems, health communications devices, and technology for the growing personal safety and care economy, [...]
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
11/03/2026
-- Issues Statement in Response to DOMA’s Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: [...]
RadNet, Inc. to Present at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12th
11/03/2026
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT ), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that [...]
Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2025 Financial Results
11/03/2026
Full Year 2025 Sales Increased to $59.1 Million, Up 2.3%, Compared to $57.8 Million for the Full Year of 2024 Net sales for the year ended December 31, 2025, were $59.1 million, up 2.3% compared to $57.8 million for the [...]
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
11/03/2026
Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
11/03/2026
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference [...]
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
11/03/2026
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
11/03/2026
ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company. Attachments notification-of-managers [...]
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
11/03/2026
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $ [...]
GUERBET : Evolution du Conseil d’Administration de Guerbet.
11/03/2026
Evolution du Conseil d’Administration de Guerbet Villepinte, le 11 mars 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination ce [...]
GUERBET : Change in Guerbet’s Board of Directors.
11/03/2026
Change in Guerbet’s Board of Directors Villepinte, March 11th, 2026: Guerbet (FR0000032526 GBT), a global leader in contrast agents and solutions for medical imaging, today announced, at its Board of Directors’ meeting [...]
Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000
11/03/2026
CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of [...]
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
11/03/2026
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early [...]
GUERBET : Résultats annuels 2025.
11/03/2026
Résultats annuels 2025 Chiffre d’affaires : 786,4 M€, soit un repli de 3,5% à TCC 1 et périmètre comparable 2 , dû essentiellement à la baisse de l’activité en France Rentabilité : la marge d’EBITDA retraité 3 ressort à [...]
GUERBET : 2025 full-year results.
11/03/2026
2025 full-year results Revenue : €786.4 million, down 3.5% at CER 1 and like-for-like 2 , mainly due to the fall in activity in France Profitability : restated EBITDA margin 3 of 12.0% (at the high end of the adjusted [...]

Pages